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Abstract
Background: The incidence of cirrhosis and hepatocellular carcinoma (HCC) is in-
creased in Type 2 diabetes, primarily secondary to non-alcoholic fatty liver disease 
(NAFLD). European guidelines recommend screening for NAFLD in Type 2 diabetes. 
American guidelines, while not advocating a screening protocol, suggest using non-
invasive markers of fibrosis for risk-stratification and guiding onward referral.
Aims: To test the ability of individual fibrosis scores and the European screening al-
gorithm to predict 11-year incident cirrhosis/HCC in an asymptomatic community 
cohort of older people with Type 2 diabetes.
Methods: The Edinburgh Type 2 Diabetes Study investigated men and women with 
Type 2 diabetes (n = 1066, aged 60–75 at baseline). Liver markers were measured at 
baseline and year 1; steatosis and fibrosis markers were calculated according to inde-
pendently published calculations. During 11 years of follow-up, cases of cirrhosis and 
HCC were identified.
Results: Forty-three out of 1059 participants with no baseline cirrhosis/HCC devel-
oped incident disease. All scores were significantly associated with incident liver dis-
ease by odds ratio (P < .05). The ability of the risk-stratification tools to accurately 
identify those who developed incident cirrhosis/HCC was poor with low-positive pre-
dictive values (5-46%) and high false-negative and -positive rates (up to 60% and 77%) 
respectively. When fibrosis risk scores were used in conjunction with the European 
algorithm, they performed modestly better than when applied in isolation.
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1  | INTRODUC TION
People with Type 2 diabetes have a higher incidence of cirrhosis and 
hepatocellular carcinoma (HCC) than the general population.1-3 The 
commonest cause of liver disease in Type 2 diabetes is non-alcoholic 
fatty liver disease (NAFLD) with estimates of prevalence from 40% 
to 70%.4-7
It would be valuable to identify those at high risk of develop-
ing cirrhosis/HCC because NAFLD (at the pre-cirrhotic stage) is 
potentially reversible by weight loss, and it would direct screening 
and early treatment for varices and HCC, while promoting intensive 
management of increased cardiovascular risk.8,9
A significant problem in creating appropriate risk assessment 
tools for NAFLD is that no consistent risk factors for progressive dis-
ease have been identified. Cohort studies report variable results and 
in meta-analyses the only consistent factor predicting progressive 
disease is histological identification of liver fibrosis.10,11 However, 
liver biopsy is an invasive procedure, with a complication rate that is 
not acceptable for population screening. Several groups have devel-
oped non-invasive risk scoring models to identify those with fibro-
sis (including the Fibrosis 4 Index (FIB-4), the NALFD Fibrosis Score 
(NFS), AST:ALT ratio, the AST to Platelet Ratio Index (APRI) and the 
Enhanced Liver Fibrosis test (ELF)).12-16 These scores have been val-
idated in cohorts with NAFLD. However, subsequent studies have 
shown variable performance with the strength of association with 
incident cirrhosis, HCC, the need for liver transplantation and death 
varying significantly between cohorts.17-21 Most of these studies 
have been small and only included people under secondary care 
hepatology services. In addition, when applied to specific groups, 
literature based cut-offs result in very variable proportions of popu-
lations being classed as ‘high risk’ with poor agreement between the 
top 5% of the distribution of risk scores.22,23
Consensus guidelines on the management of NAFLD, pub-
lished by the European Association for the Study of the Liver, the 
European Association for the Study of Diabetes and the European 
Association for the Study of Obesity (EASL-EASD-EASO) recom-
mend screening for NAFLD as part of routine care in Type 2 diabe-
tes.8 These guidelines suggest a screening algorithm that advises 
referral for specialist hepatology assessment if there is evidence 
of steatosis and non-invasive markers suggest medium or high risk 
of fibrosis; or if there is a raised alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) or gamma-glutamyltransferase 
(γGT) (Figure 1). The American Association for the Study of Liver 
Diseases (AASLD), while not recommending a specific screening 
algorithm, states that there should be ‘a high index of suspicion for 
NAFLD and NASH in Type 2 diabetes’.9 The AASLD suggests the 
use of existing liver fibrosis risk scores or assessment methodol-
ogies (such as the FIB-4, NFS or transient elastography) to assess 
at-risk patients.9
One study of the EASL-EASD-EASO referral algorithm reported 
that around one third of people routinely attending a diabetes clinic 
would fulfil the criteria for hepatology referral; the incidence of 
subsequent cirrhosis and HCC in that cohort was not reported.24 
It is possible that the ability of the non-invasive tests to accurately 
identify incident disease may be affected by low event rates in com-
munity populations. Moreover, it has been suggested that current 
risk scores may be less accurate in people with Type 2 diabetes than 
in those without.25 There remains significant uncertainty about the 
utility of these screening methods in Type 2 diabetes.
2  | AIMS
We aimed to assess the ability of individual fibrosis scores and of the 
EASL-EASD-EASO screening algorithm to predict 11-year incident 
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Lay summary
The incidence of end-stage liver disease is increased in 
people with Type 2 diabetes, primarily because of non-
alcoholic fatty liver disease. Screening for liver disease in 
Type 2 diabetes is recommended. This study showed that, 
in a cohort of older people with Type 2 diabetes, current 
recommended screening pathways did not reliably identify 
those at risk of developing end-stage liver disease.
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cirrhosis and/or HCC in an asymptomatic community cohort of older 
people with Type 2 diabetes.
3  | METHODS
3.1 | The Edinburgh type 2 diabetes study
The Edinburgh Type 2 Diabetes Study (ET2DS) is a population-based 
prospective cohort study, designed to investigate the progression of 
complications in people with Type 2 diabetes. The full methods have 
been described previously.26 In summary, in 2006/07 participants 
aged 60-74 with Type 2 diabetes were randomly selected (in age and 
sex bands) from the Lothian Diabetes Register (a database of almost 
30 000 patients with diabetes living in Lothian, Scotland, UK, man-
aged in both primary and secondary care). Invitations to participate 
were sent to 5454 people, of whom 1066 (20%) attended baseline 
assessment. These people have been shown to be representative 
of all those invited and thus of the target population.26 All who at-
tended the baseline clinic were invited to re-attend a clinical and liver 
assessment at year 1 and 4. A total of 939 attended the year 1 clinic 
(of the original baseline cohort, deceased n = 15, unable to contact 
n = 19, unable to attend n = 93) and 831 at year 4 (of the baseline co-
hort, deceased n = 88, unsuitable for clinical reasons n = 26, unable 
to contact n = 23, unable to attend n = 98). The characteristics of 
the cohort who attended the year 1 clinic were similar to the whole 
cohort at baseline.6 All 1066 participants were followed up for out-
come assessment to death (320 participants throughout the study) 
or end of follow-up.
3.2 | Data collection—baseline 
biomarker assessment
Research clinics were undertaken at the Wellcome Trust Clinical 
Research Facility, Western General Hospital, Edinburgh, UK. 
F I G U R E  1   EASL-EASD-EASO 
algorithm (with permission of the initial 
publisher). Diagnostic flow-chart to 
assess and monitor disease severity 
in the presence of suspected NAFLD 
and metabolic risk factors. 1Steatosis 
biomarkers: Fatty Liver Index, Steato 
Test, NAFLD Fat score (see Tables). 2Liver 
tests: ALT AST, γGT. 3Any increase in 
(FibroTest, FibroMeter, ELF). 5Low risk: 
indicative of no/mild fibrosis; Medium/
high risk: indicative of significant fibrosis 
or cirrhosis
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Standardized operating procedures were used for every aspect of 
data collection as previously detailed.26 ALT, AST, γGT, platelets and 
triglycerides were measured on fasting venous samples at the base-
line research clinic and were analysed using a Vitros Fusion chemistry 
system (Ortho Clinical Diagnostics, Bucks, UK). The Enhanced Liver 
Fibrosis test (ELF) was measured on fasting venous blood samples 
from the year 1 clinic and was analysed using the ADVIA Centaur im-
munoassay system (Siemens Healthcare Diagnostics Inc., New York, 
USA) at the iQur laboratory (London, UK). Ultrasound was undertaken 
at the year 1 clinic following a 4-hour fast (Sonoline Elegra Ultrasound 
Imaging System (Siemens Medical Systems Inc., Washington, USA)). 
Ultrasounds were graded for hepatic steatosis using established cri-
teria (0=normal liver, 1=indeterminate, 2=mild steatosis, 3=severe 
steatosis) and validated by three different graders and 1H MRI spec-
troscopy in a subset, as previously described.27 This showed a median 
fat fraction in those with ‘severe’ steatosis of 19.4% (interquartile range 
12.9-27.5), compared to 4.1% (interquartile range 3.1-8.5) in those with 
‘indeterminate’/ ‘mild’ steatosis and 4.2% (interquartile range 1.2-5.7) 
in those with ‘no steatosis’. As a result of this validation which showed 
significant overlap between grade 0-2 steatosis, only those with grade 
3 steatosis on ultrasound assessment were deemed to have ‘definite 
steatosis’. Individuals with an ultrasound grading of 0-2 were consid-
ered to have ‘no definite steatosis’.
Participants underwent full diagnostic liver screen (including 
Hepatitis B and C serology, liver autoantibody titres, alpha-foeto 
protein, ferritin) and history to assess alcohol status, medication use 
and past medical history. Any participant with routine liver enzyme 
tests above the laboratory upper limit of normal (ALT >50 U/L, AST 
>45 U/L, γGT >55 U/L, alkaline phosphatase >125 U/L), AST:ALT 
ratio >1, hyaluronic acid >100 µ g/L (in the absence of known joint 
disease), positive liver autoantibodies, ferritin >1000 ng/mL, al-
pha-foeto protein >6 ng/mL, positive hepatitis B or C serology, 
spleen diameter >13 cm, platelets <150 × 109/L in the absence of 
known haematological cause, or suspected cirrhosis on ultrasound 
was referred for specialist hepatology review.
Steatosis and Fibrosis scores were calculated and cut-off levels 
used as per published literature. 
• AST to platelet ratio index (APRI) was calculated as: ((AST(U/L)/
Upper limit normal) /platelets(×109/L)) ×100. Cut-point low to 
medium/high risk of fibrosis >0.5.12
• AST: ALT ratio was calculated as: AST(U/L)/ALT(U/L). cut-point 
≥0.816.
• Fibrosis-4 index (FIB-4) was calculated as ((age(years) ×AST(U/L))/
(plt(×109/L)xsqrt ALT(U/L))). Cut point low-medium risk ≥1.3 and 
medium-high risk >2.67.13,17,28
• NAFLD Fibrosis Score (NFS) was calculated as: 
1.675+(0.037×age(years))+(0.094×BMI(kg/m2))+(1.13×IFG/dia-
betes (yes=1, no=0))+(0.99× (AST(U/L)/ALT(U/L))- (0.013xplatelet 
count(×109/L))-(0.66×albumin (g/dL)). Cut-point for low-medium 
risk ≥-1.455, medium-high risk >0.676.14
• Fatty liver index (FLI) was calculated as: ey/(1+ey)×100 where 
y = 0.953 × ln(triglycerides, mg/dl) + 0.139 × BMI, kg/m2 + 0.718 
× ln (γGT, U/L) + 0.053 × waist circumference, cm – 15.745).29
The EASL-EASD-EASO referral decision algorithm (Figure 1) was 
used.8
3.3 | Data collection—identification of liver disease
Possible prevalent liver disease was identified through a patient clini-
cal history questionnaire at the baseline clinic. Possible cases were 
confirmed if a clinician diagnosis was recorded in primary or second-
ary care medical records.
Incident cirrhosis and HCC cases were identified and corrob-
orated using multiple sources of information: retrospective re-
view of all participants’ secondary care medical notes (TrakCare, 
InterSystems Corp., Cambridge, USA), patient and GP question-
naires provided at year 4 and year 10 follow-up, ISD (Information 
Services Division, NHS Scotland) discharge summary coding of hos-
pital admissions and death coding (data from year 0-8). Cases were 
confirmed if a clinician diagnosis was recorded in secondary care 
medical notes. Participants were identified as having ‘screen-de-
tected’ cirrhosis/HCC if they were referred to hepatology as a re-
sult of year 1 or 4 investigation and remained under hepatology 
follow-up until definitive diagnosis was made. Prevalence and 10-
year incidence data from the Year 1 cohort have previously been 
reported; these data include only those individuals who attended for 
the year 1 visit, by contrast with this study which has reported data 
from the entire cohort.30
3.4 | Data analysis
Data were analysed using R (R Core Team (2017). R: A language and 
environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. URL https://www.R-proje ct.org/.). 
Logistic regression was used to identify the strength of association 
between baseline prediction scores and incident cirrhosis/HCC in 
our cohort. Complete case analysis was undertaken; <5% data were 
missing for any variable with the exception of ELF and ultrasound 
measurement (calculated at year 1 attendance; (n = 681 for ELF, 
n = 933 for ultrasound). Aikaike Information Criterion (AIC) and 
C-statistic were used to assess performance of the regression mod-
els. C-statistic assesses discrimination (the ability for a model to cor-
rectly identify those in two different groups). In logistic regression 
it is calculated as a comparison between the odds of each individual 
having the outcome based on the model variables and the actual 
outcome achieved and examines if the model performs better than 
chance; a value of >0.8 considered to be good. AIC assesses overall 
model performance using a combination of discrimination and cali-
bration (the ability of the model to rank increased risk appropriately); 
it has no scale, but lower values suggest improved performance. 
Because of our mixed population of screen-detected and clinician-
diagnosed outcomes, possibly skewing our time-to-event data as 
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those who were screen-detected were often diagnosed at a pre-
symptomatic stage, our primary analysis (logistic regression) does 
not include a time component. We additionally ran a sensitivity anal-
ysis using competing risks regression to assess whether there was a 
significant impact of the competing risk of non-liver death on model 
performance. The Bayesian Information Criterion (BIC) was used to 
assess model performance for the competing risks regression, with 
lower values suggesting improved performance. Performance was 
additionally assessed through calculation of sensitivity, specificity, 
positive predictive value, negative predictive value, false-positive 
and false-negative level.
3.5 | Ethics
Ethical permission for the study was granted by Lothian Medical 
Research Ethics Committee (REC reference 16/SS/0098). All partici-
pants gave written informed consent.
4  | RESULTS
4.1 | Subject characteristics at baseline
Participants were aged 60-74 years (mean 67.9), 51.3% male. Mean 
duration of Type 2 diabetes was 8 years, mean HbA1c 57 mmol/mol 
(7.4%) and mean BMI 31.4 kg/m2. Alcohol intake was above recom-
mended limits in 19.9% and 14.4% were current smokers (Table 1). 
Seven people had prevalent cirrhosis/HCC.
4.2 | Incident cirrhosis/HCC
Out of 1059 people without cirrhosis/HCC at baseline, 43 devel-
oped this outcome over 11 years of follow-up (11-year incidence 
4.1%) (Figure 2). Twenty-three cases were ‘screen-detected’ from 
year 1 clinic, and eight from year 4 clinic. Twelve cases were di-
agnosed following clinical referral. Range of time to diagnosis 
overlapped between the ‘screen-detected’ group (163-2251 days) 
and the ‘clinician-detected’ group (920-3977 days). Out of the 43 
people identified with cirrhosis/HCC, 37 cases were attributed to 
NAFLD, NAFLD with alcohol above the recommended limit as a 
cofactor, or mixed aetiology NAFLD and alpha-1-antitrypsin defi-
ciency; 30 developed cirrhosis, nine both cirrhosis and HCC and 
four HCC. Of those with cirrhosis, 58% developed varices, ascites 
and/or encephalopathy. This equated to an 11-year incidence of 
3.7% (3.66/ 1000 person years) (cirrhosis) and 1.2% (1.31/ 1000 
person years) (HCC).
4.3 | Performance of fibrosis risk scores in 
predicting incident cirrhosis/HCC
Table 2 describes the association of existing fibrosis risk scores, 
using published cut-points, with the development of cirrhosis/HCC. 
All risk scores revealed a significant relationship by odds ratio (OR) 
with incident cirrhosis/HCC (P < .05). Confidence intervals for the 
OR were wide. The score with the highest C-statistic was APRI (cut-
point >0.5), that with the lowest AIC was ELF (cut-point ≥10.51).
The ability of the risk scores to correctly identify people who de-
veloped cirrhosis/HCC was variable (sensitivity 33-93%, specificity 
22-98%, PPV 5-46%) The NPV’s for all scores were 97-99%, proba-
bly because the outcome (cirrhosis/HCC) was relatively rare. All ex-
cept two scores had false-negative rates >20% (with some 60%). For 
example using FIB-4 (cut-point >2.67) or AST:ALT (cut-point ≥0.8), 
24 out of 40 people who developed cirrhosis/HCC were wrongly 
classified as ‘low risk’. For scores with false-negative rates <20%, the 
false-positive rates were very high (41-78%); indicating that if a score 
was used where a false negative was less likely, a significant propor-
tion of the population who would not develop cirrhosis/HCC would 
be classified as ‘high risk’. For example using NFS (cut-point ≥1.455), 
806 people would have been classified as ‘high risk’ (of whom only 
37 developed cirrhosis/HCC). Using APRI (the score with the best 
performing C-statistic), 19/40 people who developed incident cir-
rhosis/HCC would have been classified as ‘low risk’; 78 people would 
have been classified as ‘high risk’ and referred, of whom 21 devel-
oped cirrhosis/HCC.
4.4 | Performance of the EASL-EASD-EASO 
algorithm in predicting incident cirrhosis/HCC
Table 2 describes how the EASL-EASD-EASO algorithm outcome 
was associated with the development of cirrhosis/HCC in our cohort. 
TA B L E  1   Baseline characteristics of the study population
Baseline characteristic
ET2DS population 
( n = 1066)
Age (years) 67.9 (4.2)
Sex (male) 547 (51.3)
Scottish Index of 
Multiple Deprivation 
quintile
1 (most deprived) 12 (11.9)
2 208 (19.5)
3 188 (17.6)
4 194 (18.2)
5 (least deprived) 349 (32.7)
Duration Type 2 diabetes (years) 8.1 (6.5)
HbA1c (%) 7.4 (1.1)
HbA1c (mmol/mol) 57.0 (12.0)
BMI (kg/m2) 31.4 (5.7)
Smoker (current) 154 (14.4)
Alcohol (excess)a  207 (19.9)
Note: Values are mean (SD) or n (%).
aDefined as females >14 units/week, males >21 units/week or patient 
disclosed history of a current or prior alcohol problem. 
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Different steatosis and fibrosis scores were used within this algorithm 
to see whether combinations of different scores within the algo-
rithm affected algorithm performance. No significant difference was 
observed in how well the algorithm ‘advise to refer’ outcome asso-
ciated with incident cirrhosis/HCC based on the marker of steatosis 
used (Table 2). Irrespective of the fibrosis score used in the algorithm, 
F I G U R E  2   Cirrhosis and HCC events at baseline and through 11-year follow-up
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people categorized as requiring referral were significantly more 
likely to develop cirrhosis/HCC (OR’s range 0.1-13.7 with wide CIs, 
all P < .05). When used within the algorithm, the fibrosis score that 
resulted in the greatest ability to discriminate and appropriately as-
sociate algorithm ‘advise to refer’ outcome with cirrhosis/HCC was 
APRI, based on a C-statistic of 0.82. AIC was lowest when ELF was 
used within the algorithm, though APRI provided not dissimilar AIC 
performance.
The algorithm, regardless of steatosis marker or fibrosis score in-
serted, performed variably in how the ‘advise to refer’ outcome asso-
ciated with incident cirrhosis/HCC (sensitivity 79%-90%, specificity 
36%-73%). PPV was low (5-10%) indicating that a ‘advise to refer’ out-
come was not a good predictor of incident cirrhosis/HCC. NPV was 
high at 99% but may again reflect the relative rarity of the outcome. 
False-negative rates were lower when using algorithm compared to 
fibrosis score alone, but were still 10-20%, which would have resulted 
in 4-8/40 who developed cirrhosis/HCC being classified as ‘low risk’. 
False-positive rates ranged from 27-64%, with higher false-positive 
rates seen in using risk score combinations with lower false-negative 
rates. This again demonstrates that if scores are chosen that reduce 
the number who were at true risk of cirrhosis/HCC to being classified 
as ‘low risk’, a very large number of people who are not at risk of de-
veloping cirrhosis/HCC over 11 years would be advised to be referred 
to hepatology. For example using NFS (cut-off ≥1.455), 671 people 
would obtain a ‘advise to refer’ outcome, of whom only 36 developed 
cirrhosis/HCC. Using APRI, the model with the highest C-statistic, 
8/40 people who developed incident cirrhosis/HCC would have been 
classified as ‘low risk,’ whereas 306 (using ultrasound steatosis as the 
steatosis marker) and 313 (using the FLI steatosis score as steatosis 
marker) would have been classified as ‘high risk’ and referral advised, 
with only 32 of those developing incident cirrhosis/HCC.
4.5 | Sensitivity analysis
Two sensitivity analyses were undertaken. The first demonstrates 
that there is no improvement in test performance when an outcome 
of ‘presence of varices, ascites or encephalopathy in the context of 
cirrhosis or HCC’ was used (Table 3). The second excluded all those 
with definite non-NAFLD disease (n = 3) and showed similar results 
TA B L E  2   Performance of Fibrosis scores in prediction of 11-year incident cirrhosis/HCC
Fibrosis score (cut-
point value used) OR (95% CI)
Sens (%, 
95% CI)
Spec (%, 
95% CI)
PPV (%, 95% 
CI)
NPV (%, 95% 
CI)
False +ve
n (%)
False –ve
n (%)
Individual scores
ELF (≥10.51)a  30.4 (11.3-83.5)*** 39 (22-59) 98 (97-99) 46 (26-67) 97 (96-98) 13 (2) 17 (61)
APRI (>0.5) 23.7 (11.5-49.8)*** 53 (36-68) 94 (93-96) 27 (18-39) 98 (97-99) 57 (6) 19 (48)
AST:ALT (≥0.8) 3.9 (2.1-7.6)*** 41 (26-58) 26 (23-29) 2 (1-14) 92 (88-95) 261 (26) 24 (59)
NFS (≥-1.455) 3.7 (1.3-15.6)* 93 (80-98) 22 (20-25) 5 (3-6) 99 (96-100) 769 (78) 3 (8)
NFS (>0.676) 8.2 (4.2-15.9)*** 45 (29-62) 91 (89-93) 17 (10-26) 98 (96-98) 88 (9) 22 (56)
FIB 4 (≥1.3) 8.1 (3.7-20.6)*** 82 (67-93) 59 (56-63) 8 (5-11) 99 (98-100) 402 (41) 7 (18)
FIB 4 (>2.67) 39.5 (17.4-91.9)*** 40 (25-57) 98 (97-99) 46 (29-63) 98 (96-98) 19 (2) 24 (60)
Scores used within EASL-EASD-EASO algorithm, uss steatosis as steatosis marker
ELF (≥10.51)a  10.1 (4.6-25.6)*** 82 (66-92) 66 (63-69) 10 (7-14) 99 (97-99) 276 (34) 7 (18)
APRI (>0.5)a  13.0 (6.1-31.0)*** 80 (64-91) 73 (70-75) 10 (7-14) 99 (98-100) 274 (27) 8 (20)
AST:ALT (≥0.8)a  7.7 (3.7-16.7)*** 80 (65-91) 63 (60-66) 8 (6-11) 99 (98-99) 367 (37) 8 (20)
NFS (≥-1.455)a  6.0 (2.5-17.6)*** 88 (73-96) 44 (41-47) 6 (4-9) 99 (97-100) 527 (56) 5 (13)
FIB 4 (≥1.3)a  11.7 (5.0-34.5)*** 88 (73-96) 60 (57-64) 8 (6-11) 99 (98-100) 384 (40) 5 (13)
Scores used within EASL-EASD-EASO algorithm, fatty liver index as steatosis marker
ELF (≥10.51)a  9.1 (4.3-21.7)*** 79 (64-91) 67 (64-70) 10 (7-14) 99 (97-99) 277 (33) 8 (21)
APRI (>0.5) 12.6 (5.9-30.1)*** 80 (64-91) 72 (69-75) 10 (7-14) 99 (98-100) 281 (28) 8 (20)
AST:ALT (≥0.8) 10.0 (5.0-20.0)*** 76 (60-88) 73 (70-76) 10 (7-14) 99 (98-99) 273 (27) 10 (24)
NFS (≥-1.455) 5.6 (2.2-19.0)** 90 (76-97) 36 (33-39) 5 (4-7) 99 (97-100) 635 (64) 4 (10)
FIB 4 (≥1.3) 13.7 (5.4-46.2)*** 90 (76-97) 58 (55-61) 8 (6-11) 99 (98-100) 422 (42) 4 (10)
Note: AIC and C statistic documented in Supporting Information 1.
Abbreviations: OR, odds ratio (age and sex adjusted); sens, sensitivity; spec, specificity; PPV, positive predictive value; NPV, negative predictive 
value; ELF, enhanced liver fibrosis panel; NFS, NAFLD fibrosis score; APRI, AST:Platelet ratio index; FIB 4, fibrosis 4 index; EASL-EASD-EASO, 
European Association for the Study of the Liver, the European Association for the Study of Diabetes and the European Association for the Study of 
Obesity algorithm (Figure 1).
a ELF and ultrasound measured at year 1 only- so calculated 10 not 11-year incident cirrhosis/HCC. 
*P < .05, **P < .01, ***P < .001. 
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to those presented for the whole cohort with mixed aetiology dis-
ease above (Supporting Information 2).
Additionally, analysis was re-run using competing risks regression 
methodology with the competing risk being non-liver death. Results 
were similar to those obtained from logistic regression methodology 
with all risk scores showing a significant association with the devel-
opment of cirrhosis/HCC and APRI providing the best improvement 
from null model by BIC (Supporting Information 3).
5  | DISCUSSION
In this study cohort of older people with Type 2 diabetes, during 
11 years of follow-up a moderate rate of incident cirrhosis (3.66 
per 1000 person years) and HCC (1.31 per 1000 person years) was 
identified. These are substantially higher than reported population 
rates (0.36-0.54 per 1000 person-years for cirrhosis; 0.41-0.58 
per 1000 person years for ‘liver cancer’) (www.isdsc otland.org) 31. 
However, despite these findings (and consistent with other studies 
showing that Type 2 diabetes is a risk factor for the development 
of cirrhosis/HCC), the performance of existing non-invasive risk 
stratification tools in identifying those at risk of developing disease 
was poor.
A significant association was demonstrated between all NAFLD 
fibrosis risk scores, and the EASL-EASD-EASO algorithm ‘advise to 
refer’ outcome, and incident cirrhosis/HCC by OR. However, con-
fidence intervals of the OR were wide. The model that yielded the 
highest C-statistic, both in isolation, and as part of the EASL-EASD-
EASO algorithm, suggesting best discriminatory ability, was APRI 
with a cut point of >0.5. However, this score in isolation would have 
resulted in 47.5% (19/40) people who developed cirrhosis/HCC being 
classified as ‘low risk’. Using APRI within the EASL-EASD-EASO al-
gorithm, 20% (8/40) people who developed cirrhosis/HCC would 
have been classified as ‘low risk’ (received a ‘do not refer’ outcome), 
whereas 29% (306 or 313 individuals using ultrasound steatosis or 
FLI respectively) would have been classified as ‘high risk’ (receiving 
a ‘advise to refer’ outcome), with only 32 of those developing cir-
rhosis/HCC over 11 years. Using any model, significant numbers of 
people would have been classified as ‘high risk’ who did not develop 
cirrhosis/HCC over 11 years, whereas a large proportion of those 
who developed cirrhosis/HCC would have been classified inappro-
priately as ‘low risk’. It is important to note that many of the risk 
TA B L E  3   Performance of Fibrosis scores in prediction of 11-year incident cirrhosis-related varices, ascites, encephalopathy or HCC
Fibrosis score (cut-
point value used) OR (95% CI)
Sens (%, 
95% CI)
Spec (%, 
95% CI)
PPV (%, 
95% CI)
NPV (%, 95% 
CI)
False +ve
n (%)
False –ve
n (%)
Individual scores
ELF (≥10.51)a  25.41 (8.45-76.40)*** 38 (18-62) 98 (96-99) 33 (16-55) 98 (97-99) 16 (2) 13 (62)
APRI (>0.5) 31.30 (13.57-75.97)*** 61 (41-78) 94 (92-95) 22 (13-33) 94 (92-95) 61 (6) 11 (39)
AST:ALT (≥0.8) 5.50 (2.55-12.57)*** 34 (18-54) 26 (23-29) 1 (1-2) 93 (90-96) 754 (74) 19 (66)
NFS (≥-1.455) 4.05 (1.18-25.44) 93 (76-99) 22 (20-25) 3 (2-5) 99 (97-100) 780 (78) 2 (7)
NFS (>0.676) 8.48 (3.85-18.47)*** 46 (28-66) 91 (89-92) 12 (7-20) 98 (97-99) 93 (9) 15 (54)
FIB 4 (≥1.3) 15.67 (5.28-67.35)*** 89 (72-98) 59 (56-62) 6 (4-8) 99 (99-100) 410 (41) 3 (11)
FIB4 (>2.67) 59.99 (24.00-157.79)*** 50 (31-69) 98 (97-99) 40 (24-58) 99 (98-99) 21 (2) 14 (50)
Scores used within EASL-EASD-EASO algorithm, uss steatosis as steatosis marker
ELF (≥10.51)a  6.32 (2.75-16.36)*** 75 (55-89) 65 (62-69) 7 (4-10) 99 (97-99) 286 (35) 7 (25)
APRI (>0.5)a  10.74 (4.51-29.76)*** 79 (59-92) 72 (69-75) 7 (5-11) 99 (98-100) 284 (28) 6 (21)
AST:ALT (≥0.8)a  5.45 (2.41-13.97)*** 76 (56-90) 62 (59-65) 6 (3-8) 99 (98-100) 378 (38) 7 (24)
NFS (≥-1.455)a  3.70 (1.51-11.14)** 82 (63-94) 44 (40-47) 4 (3-6) 99 (97-100) 539 (56) 5 (18)
FIB 4 (≥1.3)a  7.34 (2.98-22.07)*** 82 (63-94) 60 (57-63) 5 (4-8) 99 (98-100) 396 (40) 5 (18)
Scores used within EASL-EASD-EASO algorithm, fatty liver index as steatosis marker
ELF (≥10.51)a  6.53 (2.84-16.89)*** 75 (55-89) 66 (63-69) 7 (4-10) 99 (97-100) 287 (34) 7 (25)
APRI (>0.5) 10.47 (4.40-29.01)*** 79 (59-92) 71 (68-74) 7 (4-10) 99 (98-100) 291 (29) 6 (21)
AST:ALT (≥0.8) 7.52 (3.07-22.54)*** 83 (64-94) 60 (57-63) 6 (4-8) 99 (98-100) 407 (40) 15 (17)
NFS (≥-1.455) 4.96 (1.71-21.00)** 89 (72-98) 36 (33-39) 4 (2-5) 99 (98-100) 646 (64) 3 (11)
FIB 4 (≥1.3) 12.23 (4.23-51.78)*** 89 (72-98) 57 (54-60) 5 (4-8) 99 (98-100) 433 (43) 3 (11)
Abbreviations: OR, odds ratio (age and sex adjusted); sens, sensitivity; spec, specificity; PPV, positive predictive value; NPV, negative predictive 
value; ELF, enhanced liver fibrosis panel; NFS NAFLD, fibrosis score; APRI, AST:Platelet ratio index; FIB 4, fibrosis 4 index, EASL-EASD-EASO, 
European Association for the Study of the Liver, the European Association for the Study of Diabetes and the European Association for the Study of 
Obesity algorithm (Figure 1).
a ELF and ultrasound measured at year 1 only- so calculated 10 not 11-year incident cirrhosis/HCC. 
*P < .05, **P<.01, ***P < .001. 
     |  9GRECIAN Et Al.
scores were designed to identify advanced fibrosis as opposed to 
cirrhosis/HCC. However, given the time span of follow-up we would 
have expected those with advanced fibrosis to progress to cirrhosis 
over 11 years and there thus to be a correlation. In addition, a sig-
nificant proportion of our population underwent ultrasound at year 
1. All abnormal ultrasounds were followed up and those diagnosed 
with fibrosis at year 1 progressed to cirrhosis over the period of the 
study.
ET2DS is a study of moderate size that has reviewed long-term 
liver outcomes in individuals with Type 2 diabetes who were as-
ymptomatic of liver disease at baseline. Almost all other studies 
have examined outcomes in people recruited from secondary care 
hepatology clinics, with known NAFLD and a higher likelihood of 
cirrhosis/HCC. Although the ET2DS studied a cohort at higher risk 
of cirrhosis/HCC than the general population, the absolute proba-
bility of cirrhosis/HCC was moderately low. Therefore, validated 
risk scores and a European consensus algorithm have been tested 
in a cohort where the pre-test probability is low; in contrast to pre-
vious studies. However, this represents precisely the scenario in 
which European guidelines recommend screening for liver disease. 
Participants in the ET2DS were well characterized at baseline allow-
ing accurate documentation of baseline risk factors, and have been 
followed longitudinally and extensively using multiple sources of 
information.
There are limitations to our study. ET2DS is a single centre study, 
undertaken in people aged 60-75 years, of predominantly Caucasian 
origin (98.3%). Whilst this was a representative sample of people 
with Type 2 diabetes in the population sampled (Lothian, Scotland, 
UK), care should be taken in extrapolating to other populations. All-
cause cirrhosis and HCC was investigated. While aetiology was pre-
dominantly NAFLD, individuals with advanced liver disease because 
of other causes or with known co-factors (eg alcohol above the 
NAFLD threshold) were also included. Determining the precise aeti-
ology of cirrhosis/HCC can often be difficult in a real-world setting. 
It is likely that some individuals had liver disease where both alcohol 
and obesity contributed, therefore including individuals with all-
causes of liver disease seemed more clinically relevant. A sensitivity 
analysis excluding the three participants who had definite non-NA-
FLD disease did not reveal significantly different results (Supporting 
Information 2). Medication exposure data were not analysed, so any 
modifying effect will not have been detected.
The main outcome was cirrhosis/HCC. It is possible that some 
participants developed cirrhosis/HCC during follow-up, but were 
asymptomatic or did not seek medical advice for symptoms. These 
individuals would not have been identified as research screening for 
cirrhosis/HCC was not repeated at 11-year follow-up. A substantial 
proportion of the diagnoses were made after hepatology referral 
following year 1 and year 4 screening investigations. This has two 
implications. Firstly, as the natural history of NAFLD progression is 
very prolonged, it is possible that those who were diagnosed fol-
lowing referral from screening had cirrhosis/HCC at baseline and 
had prevalent rather than incident disease. However, the range 
of time from year 1 clinic to diagnosis overlaps significantly in the 
‘screen-detected’ and ‘clinician-detected’ groups. Moreover, sev-
eral of those who were ‘screen-detected’ were not identified with 
cirrhosis/HCC on initial hepatology review, but follow-up was con-
tinued because of concern regarding ‘high-risk’ features and they 
were diagnosed with cirrhosis/HCC several years later. Therefore, 
we defined prevalent disease as that which was clinically apparent at 
baseline. Secondly, the screening process may have led to an earlier 
diagnosis of cirrhosis/HCC in some people who may have died from 
other causes before cirrhosis/HCC was clinically apparent, inflating 
incidence rates. However, 58% of those identified with cirrhosis de-
veloped varices, ascites and/or encephalopathy and 23% developed 
HCC, so while investigation may have advanced the time of diagno-
sis, many would likely have presented during the period of follow-up. 
While all other biomarkers were measured at baseline, ELF and liver 
ultrasound were undertaken at the year 1 clinic, so analyses using 
these markers have examined slightly different ‘baseline’ time points. 
However, the performance of the EASL-EASD-EASO algorithm did 
not differ when using Fatty Liver Index (measured at baseline) and 
ultrasound as the steatosis marker, so with respect to the steatosis 
assessment, it is unlikely that this had a material effect on the pres-
ent results. Because of limitations in the time to diagnosis data, both 
a logistic regression analysis and a competing risks regression ap-
proach (as a sensitivity analysis) were used. The former analysis has 
the disadvantage of not taking into account deaths during follow-up, 
whereas in the latter approach, time-to-event discrepancies may 
also introduce bias. Results of the competing risks regression were 
similar to the logistic regression assessment (Supporting Information 
3) suggesting that neither the proportion of non-liver death in our 
population nor the mixed screen-detected and clinician-detected 
events substantially affected results.
Several studies have compared non-invasive markers of fibro-
sis to clinical outcome in NAFLD, mostly undertaken in popula-
tions of people under secondary care hepatology clinic follow-up, 
who had an initial liver biopsy. Three studies (median 5-12 year 
follow-up) showed increased hazard ratios (HR) for all-cause mor-
tality, decompensated cirrhosis, rates of HCC or liver transplant 
in those with raised NFS, APRI or FIB-4 scores (16-36% partici-
pants had diabetes).17,19,20 None reported sensitivity, specificity, 
PPV or NPV. Three studies compared non-invasive scores with 
severity of fibrosis on biopsy at the time of testing and showed 
strong associations between NFS, APRI, FIB-4 and AST: ALT ratio, 
and biopsy with an area under the receiving curve of 0.7-0.88, de-
pending on score used (19-50% participants had diabetes).16,28,32 
However, all described decreasing specificity with increasing sen-
sitivity, for risk score cut-points used. A recent study examined 
median 4 year outcomes in a cohort of 284 participants under 
hepatology clinic follow-up for NAFLD (>80% biopsy confirmed, 
53% had diabetes).25 As expected in a hepatology clinic popula-
tion, rates of cirrhosis/HCC were high (9.2% liver-related death or 
transplant, 14.8% decompensated cirrhosis, 9.9% HCC). A diagno-
sis of diabetes conferred an increased HR of developing a liver 
outcome (death/transplantation HR 3.4 (95% confidence interval 
1.2-9.1), decompensated cirrhosis HR 4.7 (2-11.3) and HCC HR 2.9 
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(1.2-7.3)). However, NFS, APRI or FIB-4 scores in the people with 
diabetes were substantially less good (by C-statistic comparison) 
at predicting outcome than in the individuals without diabetes. 
In those with diabetes, 21% of those with a ‘low-risk’ NFS, 15% 
with ‘low-risk FIB-4’ and 15% ‘low-risk’ APRI developed decom-
pensated cirrhosis, and 27% with ‘low-risk’ scores developed HCC. 
In contrast, in individuals without diabetes, no participant with a 
‘low-risk’ fibrosis score developed decompensated cirrhosis or 
HCC during follow-up. Therefore, the results of our study confirm 
what is reported in previous publications; that non-invasive risk 
scores do associate with outcome, but false-positive and -negative 
levels are high.
Current risk prediction scoring fails to identify a significant pro-
portion of people with Type 2 diabetes who develop incident cir-
rhosis/HCC. Our population representative approach implies that 
general use of current risk scores and algorithms in people with Type 
2 diabetes will result in unnecessary additional referral and investi-
gation in large numbers of people who will not develop incident cir-
rhosis/HCC over 11 years. This has significant resource implications 
for hepatology services. Our study importantly examines outcomes 
from an unselected community population, for which these screen-
ing algorithms are advocated.
It remains unclear why the fibrosis risk scores perform better 
in people without diabetes than those with diabetes. It is possible 
that there are confounders influencing the biomarkers used in the 
non-invasive scores that are affected by diabetes. For example it has 
been described that measurements of AST and ALT in mouse mod-
els are affected by hyperglycaemia.25 Future research is required to 
identify improved methods of predicting incident cirrhosis/HCC in 
this high-risk population, possibly through combining existing risk 
scores, examining whether serial monitoring is a more effective 
screening strategy or investigating novel or alternative biomarkers.
Type 2 diabetes is associated with an increased rate of cirrho-
sis/HCC.2,3 Risk prediction scores and international guidelines have 
attempted to provide non-invasive methods of assessing risk of in-
cident disease in this high-risk population. This study shows only 
modest performance of these risk scores and screening algorithm. 
Use would lead to significant pressure on hepatology services from 
high referral rates coupled with increased patient anxiety generated 
by false-positive results. Furthermore, the risk scores fail to identify 
a significant proportion of the population that are potentially vulner-
able to incident disease. Future work to improve prediction methods 
in this population is necessary.
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